Association of Urinary Epidermal Growth Factor with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition - PubMed
5 hours ago
- #kidney disease
- #biomarker
- #SGLT2 inhibitors
- Urinary epidermal growth factor-to-creatinine ratio (uEGF/Cr) serves as a marker of tubular repair capacity and is associated with kidney disease progression.
- In participants with type 2 diabetes from CANVAS and CREDENCE trials, higher baseline uEGF/Cr was linked to a lower risk of composite kidney outcomes.
- SGLT2 inhibitors attenuated the decline in uEGF/Cr over one year compared to placebo by 6.7%.
- Increases in uEGF/Cr from baseline to year one were independently associated with reduced kidney risk, even after adjusting for changes in albuminuria and eGFR.
- Similar results were replicated in the DAPA-CKD trial, confirming consistency across populations with and without diabetes.
- The findings support uEGF/Cr as a robust biomarker of tubular health and kidney risk in diverse chronic kidney disease populations.